Skip to content
Esta página está disponible en españolCambiar →
GestorLensSign up

AgomAb Therapeutics (AGMB): which funds own it

Health Care →Data as of Jun 30, 2026 (Q2 2026) · updated on Nov 5, 2026

A 13F shows the portfolio at quarter-end and is filed up to 45 days later: these are not real-time positions and they may have changed.

Follow AGMB for free
Share

Sections with a free account

5 concentrated managers hold it with a median weight of 1.0%. 3 officers or directors bought in 6 months.

Who owns AgomAb Therapeutics?

AgomAb Therapeutics trades in the U.S. through ADRs, certificates that represent shares of a non-U.S. company. Form 13F counts ADRs while the company reports ordinary shares, so we do not compute percentages. Holders reporting more than 5% of the ordinary shares to the SEC (Schedules 13D/13G): LSP 7 Cooperatieve U.A., 10.6% (13D filed Feb 17, 2026), FMR, 10.0% (13G filed Mar 6, 2026), Pontifax VI G.P., 6.8% (13G filed Apr 16, 2026), Sanofi, 5.7% (13G filed May 6, 2026) and Redmile Group, 5.6% (13G filed May 15, 2026). As of Jun 30, 2026, the largest ADR holders reported on Form 13F were EQT Fund Management S.a r.l (5.1 million ADRs), Sanofi (2.8 million ADRs) and Redmile Group (2.7 million ADRs).

Which institutions hold the most AgomAb Therapeutics shares?

Per Form 13F filings as of Jun 30, 2026, in ADRs:

  1. 1. EQT Fund Management S.a r.l: 5.1 million ADRs
  2. 2. Sanofi: 2.8 million ADRs
  3. 3. Redmile Group: 2.7 million ADRs
  4. 4. Cormorant Asset Management: 2.5 million ADRs
  5. 5. TCG Crossover Management: 2.1 million ADRs
  6. 6. Federated Hermes: 1.6 million ADRs
  7. 7. Nantahala Capital Management: 1.6 million ADRs
  8. 8. Casdin Capital: 1.6 million ADRs
  9. 9. Andera Partners: 1.5 million ADRs
  10. 10. FMR: 1.5 million ADRs

Sources:13D by LSP 7 Cooperatieve U.A. (Feb 17, 2026) ↗13G by FMR (Mar 6, 2026) ↗13G by Pontifax VI G.P. (Apr 16, 2026) ↗13G by Sanofi (May 6, 2026) ↗13G by Redmile Group (May 15, 2026) ↗All of the company's proxy statements on EDGAR ↗

We hold 13D and 13G filings made since Dec 23, 2024: a holder above 5% that has not filed since then does not appear here.

Concentrated managers
5
All 13F: 34
Consensus
29/100
across 5 concentrated managersRanks by accumulation, portfolio weight and number of managers; it does not say more are buying than selling.
Price at Jun 30, 2026 (per 13F)
$12.98
+23.7% in the quarter · reported value ÷ shares, not the quote · See current quote ↗

Quarter flow (concentrated managers)

Change in managers (5 → 5): 0 opened · 0 exited = 0

Net flow in the quarter: +$33.5M (+2.6 M shares) · bought $33.5M and sold $0Shares concentrated managers added minus those they cut, valued at the 13F quarter-end implied price, not each trade's price. It is a different measure from the change in managers: the two can have opposite signs.

The set of concentrated managers changed between quarters: with the set as it was then, 6 held it last quarter (the chart point); with today's set, 5 (the base for the change).

Concentrated managers holding it

Up to 15, sorted by position value. The percentage is the weight in each manager's portfolio.

Largest holders of AGMB (all 13F filers)

The 10 13F filers with the most shares as of Jun 30, 2026, whatever their type (index firms usually come first). “Change”: shares added or cut versus the previous quarter, split-adjusted; “no data” = there is no comparable portfolio for the previous quarter (no filing, or a filing with its holdings under confidential treatment). “% of the company” only where shares outstanding are up to date. Entities of the same group file separately and some 13F filings include other managers: there may be double counting. With a free account: the top 25, the largest buyers and the largest sellers.

Insiders (Form 4)

Officers and directors who bought (6 m)
3
Amount (6 m)
$400K
CEO/CFO bought (12 m)
Yes

10% owners who bought (6 m): 0

Open-market purchases, excluding 10b5-1 plans. Officers and directors only; joint filers of the same purchase count as one. 10% owners with no role are shown separately. 0 = nobody bought; “no data” = we do not have its Form 4 filings.

Each of the company's Form 4 filings, on EDGAR ↗Latest trades, with date and filing →

Above 5% (13D/13G)

Disclosed stakes, with their amendments. A filing is not always a purchase: there are also reductions and changes of filing entity.

This list may be incomplete: we hold 13D and 13G filings made since Dec 23, 2024. A holder above 5% that has not filed anything since then is not shown here.

Above 5% over time (13D/13G)

Each holder with its filings in order. History since December 2024.

This company filed no 8-K forms in the last year. Foreign companies listed in the US (ADRs) report material events on forms 6-K and 20-F, and ETFs and funds do not file 8-Ks. If it is a foreign company listed in the US through ADRs (American Depositary Receipts), what trades are bank-issued certificates that represent shares from its home market. See its filings on EDGAR ↗

Other Health Care stocks in managers' portfolios

Same sector and a similar number of concentrated managers holding them. It is a list to keep exploring, not a recommendation.

All of Health Care →

Follow AGMB for free

If someone reports a 5%+ stake, we email you (if you turn it on). And when you come back, see whether concentrated managers got in or out. No credit card.

Follow AGMB